REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 31st, 2022 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of October 21, 2022, by and between Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), with its principal place of business at 3000 Pegasus Park Drive, Ste 1430, Dallas Texas, 75247 and Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) a Delaware corporation (the “Purchaser”), with its principal place of business at 600 California Street, 17th Floor, San Francisco, CA 94108 and shall become effective as of the Closing.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 31st, 2022 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 21, 2022, by and between Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), with its principal place of business at 3000 Pegasus Park Drive, Ste 1430, Dallas, Texas, 75247 and Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) a Delaware corporation (the “Purchaser”) with its principal place of business at 600 California Street, 17th Floor, San Francisco, CA 94108. Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.5.
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS AGREEMENT (INDICATED BY “[***]”) BECAUSE TAYSHA GENE THERAPIES, INC. HAS DETERMINED SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OPTION AGREEMENTOption Agreement • October 31st, 2022 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Delaware
This Option Agreement (this “Agreement”) is dated as of October 21, 2022 (the “Effective Date”) by and between Taysha Gene Therapies, Inc., with a place of business at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247 (“Taysha”) and Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) with its principal place of business at 600 California Street, 17th Floor, San Francisco, CA 94108 (“Astellas”). Taysha and Astellas may be referred to herein as a “Party” or, collectively, as “Parties”.
